Gastric Neuromuscular Function in GERD
GERD
About this trial
This is an interventional diagnostic trial for GERD
Eligibility Criteria
Healthy controls Inclusion Criteria: Aged 18-70 years old BMI 18-35 Able to understand written and spoken English Able to provide written consent Able to understand risks and benefits Exclusion Criteria: Antacid use (e.g. PPI, H2RA or Gaviscon) within last 12-months Active use of other medications known to impact gastric motility Upper GI symptoms including but not limited to heartburn, regurgitation, epigastric pain, nausea and bloating Significant medical condition History of skin allergies or hypersensitivity Active abdominal wounds or abrasions, fragile skin Current pregnancy Vulnerable group e.g. prisoners/cognitive impairment/institutionalised individuals Regular cannabis users (unable to abstain for 7-days) Opioid user Unable to use a tablet device GORD patients Inclusion Criteria Referred for 24-hour pH-impedance monitoring Aged 18-70 years old BMI 18-35 Able to understand written and spoken English Able to provide written consent Able to understand risks and benefits Exclusion Criteria Systemic or metabolic disorder known to cause gastric dysmotility other than diabetes (e.g. scleroderma, multiple sclerosis, hyperthyroidism). History of upper GI surgery or hiatal hernia (>5cm, paraesophageal, or 'large' on endoscopy report) Diabetic and on insulin Proven mechanical bowel obstruction History of skin allergies or hypersensitivity Active abdominal wounds or abrasions, fragile skin Current pregnancy Vulnerable group - prisoners/cognitive impairment/institutionalised individuals Regular cannabis users (unable to abstain for 7-days) Opioid user Unable to use a tablet device
Sites / Locations
- The Functional Gut ClinicRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Patients with medical refractory GERD
Healthy controls without gastrointestinal symptoms
Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours. Participants undergo a hydrogen and emthane breath test on a seperate day.
Participants undergo BSGM for 4.5 hours with simultaneous oesophageal manometry, pH-impedance monitoring and gastric emptying breath tests. Following completion, participants continue with ambulatory pH-impedance monitoring for a further 24-hours.